GSK Cancer R&D Chief Sees Three Key Approvals In Q2
Says “Will Help Anchor” Oncology Pipeline.
GlaxoSmithKline expects regulatory approval for three key cancer products by the middle of this year, anchoring it as a leading oncology company, Axel Hoos tells Scrip.
You may also be interested in...
US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.
The US FDA took issue with the CMC portion of the BLA for the BCMA-targeted therapy idecabtagene vicleucel for multiple myeloma. An approval is tied to a $9 CVR for Celgene shareholders.
Already working with Pfizer on the immunotherapy Bavencio, Merck KGaA has bagged another big pharma player in GSK to progress what has been heralded by analysts as the German group's oncology game changer, M7824, which combines two powerful and synergistic anticancer mechanisms into one molecule.